The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Risk of Leukemia after Platinum-Based Chemotherapy for Ovarian Cancer
Open accessAbstract
BACKGROUND: Platinum-based chemotherapy is the cornerstone of modern treatment for ovarian, testicular, and other cancers, but few investigations have quantified the late sequelae of such treatment. METHODS: We conducted a case-control study of secondary leukemia in a population-based cohort of 28,971 women in North America and Europe who had received a diagnosis of invasive ovarian cancer between 1980 and 1993. Leukemia developed after the administration of platinum-based therapy in 96 women. These women were matched to 272 control patients. The type, cumulative dose, and duration of chemotherapy and the dose of radiation delivered to active bone marrow were compared in the two groups. RESULTS: Among the women who received platinum-based combination chemotherapy for ovarian cancer, the relative risk of leukemia was 4.0 (95 percent confidence interval, 1.4 to 11.4). The relative risks for treatment with carboplatin and for treatment with cisplatin were 6.5 (95 percent confidence interval, 1.2 to 36.6) and 3.3 (95 percent confidence interval, 1.1 to 9.4), respectively. We found evidence of a dose-response relation, with relative risks reaching 7.6 at doses of 1000 mg or more of platinum (P for trend <0.001). Radiotherapy without chemotherapy (median dose, 18.4 Gy) did not increase the risk of leukemia. CONCLUSIONS: Platinum-based treatment of ovarian cancer increases the risk of secondary leukemia. Nevertheless, the substantial benefit that platinum-based treatment offers patients with advanced disease outweighs the relatively small excess risk of leukemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer Incidence in Five Continents
(1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,501
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Landis, S. H., Murray, T., Bolden, S., & Wingo, P. A. (1998) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.48.1.6 · Cited by 2,341
Statistical methods in cancer research. Vol. 1. The analysis of case-control studies
(1983) · Food and Chemical Toxicology · doi:10.1016/0278-6915(83)90281-8 · Cited by 1,716
Risk of Second Malignant Neoplasms Among Long-term Survivors of Testicular Cancer
Travis, L. B., Curtis, R. E., Fraumeni, J. F., Boice, J. D., Storm, H., Andersson, M., Hall, P., Bergfeldt, K., Holowaty, E., Clarke, E. A., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.19.1429 · Cited by 488
Self-citationLeukemia Following Hodgkin's Disease
Kaldor, J. M., Day, N. E., Clarke, E. A., Van Leeuwen, F. E., Henry-Amar, M., Fiorentino, M. V., Bell, J., Pedersen, D., Band, P., Assouline, D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001043220102 · Cited by 485
Self-citationRisk of Leukemia after Chemotherapy and Radiation Treatment for Breast Cancer
Curtis, R. E., Boice, J. D., Stovall, M., Bernstein, L., Greenberg, R. S., Flannery, J. T., Schwartz, A. G., Weyer, P., Moloney, W. C., & Hoover, R. N. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206253262605 · Cited by 446
Self-citationConcomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors.
Vokes, E. E., & Weichselbaum, R. R. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.5.911 · Cited by 364
Leukemia Following Chemotherapy for Ovarian Cancer
Kaldor, J. M., Day, N. E., Pettersson, F., Clarke, E. A., Pedersen, D., Mehnert, W., Bell, J., Høst, H., Prior, P., Karjalainen, S., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001043220101 · Cited by 279
Self-citationMelphalan May Be a More Potent Leukemogen than Cyclophosphamide
GREENE, M. H., HARRIS, E. L., GERSHENSON, D. M., MALKASIAN, G. D., MELTON, L. J., DEMBO, A. J., BENNETT, J. M., MOLONEY, W. C., & BOICE, J. D. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-105-3-360 · Cited by 175
Self-citation
Cited by
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study
Takahashi, K., Wang, F., Kantarjian, H., Doss, D., Khanna, K., Thompson, E., Zhao, L., Patel, K., Neelapu, S., Gumbs, C., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30626-x · Cited by 399
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Pediatric Cancer Survivorship Research: Experience of the Childhood Cancer Survivor Study
Leisenring, W. M., Mertens, A. C., Armstrong, G. T., Stovall, M. A., Neglia, J. P., Lanctot, J. Q., Boice, J. D., Whitton, J. A., & Yasui, Y. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1813 · Cited by 287
Self-citation
Metadata
- Authors
- Travis, L. B., Holowaty, E. J., Bergfeldt, K., Lynch, C. F., Kohler, B. A., Wiklund, T., Curtis, R. E., Hall, P., Andersson, M., Pukkala, E., Sturgeon, J., Storm, H., Clarke, E. A., Boice, J. D., Gospodarowicz, M., & Stovall, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1999-02-04
- Volume
- 340
- Issue
- 5
- Pages
- 351-357
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2313420578
- Cited by
- 359
- References
- 16
- FWCI
- 9.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of Leukemia after Platinum-Based Chemotherapy for Ovarian Cancer. https://app.cochat.ai/papers/10.1056/nejm199902043400504
- The paper
- Travis, L. B., Holowaty, E. J., Bergfeldt, K., Lynch, C. F., Kohler, B. A., Wiklund, T., Curtis, R. E., Hall, P., Andersson, M., Pukkala, E., Sturgeon, J., Storm, H., Clarke, E. A., Boice, J. D., Gospodarowicz, M., & Stovall, M. (1999). Risk of Leukemia after Platinum-Based Chemotherapy for Ovarian Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejm199902043400504
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
